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More than 450 million people globally have been found to suffer from mental 
illnesses, such as depressive disorders, schizophrenia and other mental, 
neurological disorders. Depressive disorders are currently the fourth leading 
cause of global disease burden and have been predicted by the World Health 
Organization (WHO) to rank second by 2030. Dysregulation of serotonin levels is 
believed to be one of the many causes of depressive disorders and serotonergic 
system is a common target for treatment. 
Around 1-2% of the human body’s total serotonin is synthesized and stored in the 
central nervous system, where mood, sleep and some cognitive functions are 
regulated. The rate-limiting enzyme in serotonin synthesis, Tryptophan 
hydroxylase (TPH) has two isoforms. TPH1 is mainly expressed in the peripheral 
tissues, whereas TPH2 mainly expressed in neurons and was shown to be 
associated with mental disorders from studies of mutation within the TPH2 gene. 
By investigating the fundamental mechanisms of TPH2 regulation, further 
insights on the treatment of depressive disorders could be identified. Five prime 
untranslated regions (5’UTR) of TPH2 were demonstrated to significantly impact 
gene expression. In this study, the effect of 5’UTR on regulating the gene 
expression of TPH2 in HEK and PC12 cells was investigated. 5’UTR was found 
to cause contrasting effects on TPH2 expression in the two cell lines tested by 
way of quantitative PCR (qPCR), bioluminescence assay using Renilla luciferase 
(RLuc) and doxycycline- inducible expression system (Tet-On). The regulatory 
effect of the 5’UTR on expression of heterologous genes, RLuc and enhanced 
green fluorescent protein (EGFP) genes were also investigated in the two cell 
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lines. 5’UTR when inserted upstream of the heterologous genes caused the 
RLuc activity to decrease to 52.7% (±1.82) and 56.7% (±1.82) and the EGFP 
protein level to decrease to 58.7% (±2.46) and 59.3% (±2.11) in HEK and PC12 
cells, respectively. Inhibitory effect of the 5’UTR on homologous gene, TPH2, 
expression was seen in HEK cells. Interestingly, an increase of 14.7 (±0.21) and 
1.78 (±0.01) fold in the TPH2 protein and mRNA abundance were observed in 
PC12 cells, respectively. Results also showed that the 5’UTR only upregulate 
TPH2 protein expression in PC12 cells when attached to the full length TPH2 
gene.  
It is demonstrated that 5’UTR can potentially upregulate gene expression in 
specific cell type and/or environment through an unknown mechanism. Being a 
neuronal cell line, PC12 may exhibit certain unique neural specific factors that 
might act as a positive regulator of the 5’UTR, resulting in the upregulation of 
TPH2 gene expression as herein reported. Further studies to determine potential 
factors involved in the 5’UTR upregulating effect are necessary to better 
understand the unique role of 5’UTR in gene regulation. These findings would 
supplement our understanding of TPH2 expression regulation and thus 
contribute to its potential use as a target to develop new or improved current 
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1.1. Psychiatric disorders 
1.1.1. Worldwide and Singapore Prevalence 
More than 450 million people across the globe have been found to suffer from 
mental illnesses, such as depression, schizophrenia, dementia, epilepsy, 
alcohol dependence and other mental, neurological and substance-use 
disorders (World Health Organization 2001). Mental illnesses make up 13% of 
the global disease burden, and this percentage exceeds that of both cancer 
and cardiovascular disease (Collins, Patel et al. 2011). In the last four 
decades, suicide rates have increased by 60% worldwide (World Health 
Organization 2001), with 90% of the suicide incidences involving people with 
a diagnosable mental disorder (Collins, Patel et al. 2011). The World Health 
Organization (WHO) has predicted that by 2030, depression will be the 
second and third largest contributors to the disease burden in middle and low 
income countries respectively.  
In 2011, a three-year long study conducted on the mental health status in 
Singapore revealed that the lifetime prevalence of major depressive disorder 
(MDD) was 5.8%, and more than one in ten people will suffer from a mental 
illness in their lifetime. Many are likely to face the most common mental 
illness, depression (Chong, Abdin et al. 2012). Depressive disorders and 
anxiety has been ranked as the second leading cause of disability in 2004 
(Phua, Chua et al. 2009) and in 2012, depressive disorders contributed to the 
second largest fraction of outpatient disorders, just falling shortly behind 




1.1.2. Depressive Disorders  
1.1.2.1. Types of depressive disorders 
Depressive disorders can be categorized into several forms, with MDD and 
dysthymic disorder being the most common. MDD is a disabling condition that 
is characterized by a combination of symptoms that affects a person’s general 
health and the ability to work, sleep, and eat (Belmaker and Agam 2008). 
Some patients suffer recurrences while others may experience only one 
episode. The exact cause of MDD is still unknown, although it is likely that 
various combinations of psychological, biological and environmental factors 
contribute to the development of MDD (Kessler, Berglund et al. 2003).  
Dysthymic disorder is also known as mild chronic depression, where patients 
experience symptoms over a long period, usually lasting for at least two years, 
but the symptoms are not severe enough to debilitate a person. People with 
dysthymia often feel hopeless, have low self-esteem and are unable to 
experience pleasure from activities that would usually be considered 
enjoyable (Kessler, Chiu et al. 2005, National Institute of Mental Health 2014). 
Some depressive disorders may develop under special circumstances. A 
good example will be postpartum depressions, which affect about 10-15% of 
women after giving birth (American Psychological Association 2007).   
 
1.1.2.2. Dysregulation of neurotransmitter systems in depressive 
disorders 
There have been various hypothesis proposed to explain the underlying 
etiology of depression. The most widely accepted hypothesis to date is the 
monoamine hypothesis, which suggests that dysregulated levels of 
3 
 
monoamine neurotransmitters such as serotonin, norepinephrine and 
dopamine are a major underlying cause of depression (Meyer, Ginovart et al. 
2006). Patients with depressive disorders are known to have lower levels of 
serotonin (Quan-Bui, Plaisant et al. , Jimerson, Lesem et al. 1992) or lower 
serotonin transporter binding potential (Parsey, Hastings et al. 2006, Newberg, 
Amsterdam et al. 2012). It is therefore on this basis that many of the current 
drugs on the market are developed. 
 
1.1.2.3. Current treatments 
Psychotherapy applied in combination with antidepressants is currently the 
treatment of choice for those with moderate to severe depression. 
Antidepressants are used to reduce depressive symptoms or prevent it from 
recurring. Most antidepressants work by modulating the levels of one or more 
neurotransmitters like serotonin, norepinephrine and dopamine (Omudhome 
2013), which are dysregulated in diseased states.   
There are several classes of antidepressants, including the tricyclic 
antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), selective 
serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake 
inhibitors (SNRIs). 
TCAs were the first generation of antidepressants to be developed. They 
work by blocking the serotonin transporter and the norepinephrine transporter, 
which results in the increase of the synaptic concentrations of 
neurotransmitters. However, TCAs have high affinities to many other 
receptors and also act as sodium channel and calcium channel blockers. 
These properties contribute to its numerous side effects and also the possible 
lethality from overdosing (Berling and Isbister 2014). Thus, they have since 
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fallen out of favour and have been mainly replaced by SSRIs and SNRIs, 
although they are still sometimes used to supplement other classes of 
antidepressants to increase the drug effect.  
MAOIs act by inhibiting the activity of monoamine oxidase, therefore blocking 
the breaking down of monoamine neurotransmitters and thus increasing their 
availability (Grahame-Smith 1971). When taken orally, MAOIs also inhibit the 
catabolism of dietary amines. Dietary restrictions are thus needed as MAOIs 
can cause serious high blood pressure when taken with certain foods or 
medications. An improvised route of transdermal administration of MAOIs 
appears to have fewer side effects than when consumed via the traditional 
oral route (Bodkin and Amsterdam 2002). MAOIs are usually used as a last 
resort after patients have been through treatment with other antidepressants. 
SSRIs work by preventing the reuptake of serotonin into the presynaptic 
neuron, thereby increasing the levels of available serotonin in the synaptic 
cleft to bind to postsynaptic receptors (Katrin Sangkuhl 2009). One such SSRI 
is Fluoxetine, which was introduced by Eli Lilly in 1974 (Wong, Horng et al. 
1974, Wong, Bymaster et al. 1995). Fluoxetine remains one of the most 
highly prescribed medications (Grohol 2012) for the treatment of MDD, and 
various mental disorders like obsessive compulsive disorder (Montgomery, 
McIntyre et al. 1993) and alcohol dependence (Cornelius, Bukstein et al. 
2001). Unfortunately, a large percentage of patients either fail to respond well 
to treatment, or suffer from serious side effects like nausea, insomnia and 
sexual dysfunction that arise from the usage of Fluoxetine. 
SNRIs are a newer generation of SSRIs. Most SNRIs inhibit the reuptake of 
serotonin and norepinephrine, therefore increasing the levels of both 
neurotransmitters in the synaptic cleft. Compared to TCAs, these dual 
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reuptake inhibitors have low affinities to other neurotransmitters and thus 
have lesser side effects. However sudden discontinuation of SNRIs can lead 
to withdrawal symptoms such as anxiety.  
Discovering new drugs to that have fewer side effects and improved efficacy 
in combating these diseases is one of the major foci of current research. In 
order to achieve his, a better understanding of the underlying cellular and 
molecular mechanisms of these diseases is needed. Since the serotonergic 
system is widely believed to be the main cause of the depressive disorders 
and is the basis of most of the current treatments (Blier 1990, Schloss and 
Williams 1998) , we will focus on dysregulations of this system in this thesis. 
 
1.1.3. Serotonergic system 
1.1.3.1. Serotonin and its signaling pathway in the central nervous 
system  
Serotonin (5-hydroxytryptamine, 5-HT) is a major monoamine 
neurotransmitter. More than 90% of the human body’s total serotonin is 
synthesized by the enterochromaffin cells in the mucosa of the 
gastrointestinal tract and stored in the gut and in blood platelets, where it is 
used to regulate intestinal movement (Hansen and Witte 2008) and act as a 
vasoconstrictor (Yakovlev, Spasov et al. 2014) respectively. The remaining 
few percent is synthesized and stored in the central nervous system by 
serotonergic neurons, where it plays a role in regulating mood, appetite, sleep 
and some cognitive functions.  
The main sources of serotonergic neurons in the brain are the caudal and 
rostral raphe nuclei that are located in the brainstem (Pollak Dorocic I 2014). 
Serotonergic neurons within these nuclei and their axons make up part of the 
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serotonin pathway. The caudal raphe nuclei gives rise to descending axons 
that terminates in the cerebellum and spinal cord. Whereas the rostal raphe 
nuclei axons project towards brain regions involved in higher functions such 
as the limbic regions and the basal ganglia.   
Serotonin that is released from the axons activates serotonin receptors 
located on target cell membrane. Most of the serotonin receptors are G 
protein-coupled receptors that activate intracellular second messenger 
cascades (Frazer A 1999). Only one subtype, the 5-HT3 receptor is a ligand-
gated ion channel (Kilpatrick, Bunce et al. 1990).  
 
1.1.3.2. Serotonin biosynthesis and metabolism  
There are two steps in the biosynthesis pathway of serotonin. The amino acid 
L-tryptophan is first hydroxylated by tryptophan hydroxylase (TPH) to form 5-
Hydroxy-L-tryptophan (5-HTP), which is in turn decarboxylated by aromatic L-
amino acid decarboxylase to form serotonin. The TPH-mediated step is the 
rate-limiting step in the biosynthesis pathway. Serotonin is then broken down 
by monoamine oxidase and aldehyde dehydrogenase to form the by-product, 
5-hydroxyindoleacetic acid (5-HIAA) (Goridis and Rohrer 2002).  
 
1.1.3.3. The rate-limiting enzyme, tryptophan hydroxylase 
Tryptophan hydroxylase (TPH) belong to the family of aromatic amino acid 
hydroxylases, which includes tyrosine hydroxylase and phenylalanine 
hydroxylase (Fitzpatrick 2000). Structurally, aromatic amino acid hydroxylase 
consists of three distinct domains: an N-terminal regulatory domain, a central 
catalytic domain, and a C-terminal tetramerization domain. Additionally, 
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members of this family share substantial sequence homology in all domains, 
except for the regulatory domain (Fig. 1).  
With respect to TPH, there are two isoforms (Walther and Bader 2003, 
Walther, Peter et al. 2003); TPH1 is mainly expressed in the peripheral 
tissues, whereas TPH2 is exclusively expressed in neurons (Walther, Peter et 
al. 2003, Patel, Pontrello et al. 2004).  In addition to having substantial 
sequence homology in other domains, these two isoforms of TPH also share 
substantial homology in the regulatory domain (amino acids 1-150), except for 
an additional 41 amino acids at the N-terminal of TPH2. These 41 amino 
acids that lie in the regulatory domain of TPH2 may account for the 
differences in properties between TPH1 and TPH2. For example, this 
extended N-terminus domain of TPH2 was demonstrated to be involved in the 
regulation of neuronal 5-HT synthesis (Murphy, Zhang et al. 2008). TPH2 
when expressed in mammalian cells is synthesized less efficiently and is also 
less stable as compared to TPH1. A chimeric protein was constructed with 
the first 41 amino acids of TPH2 attached to the N-terminal of TPH1 revealed 
that this extended N-terminus is responsible for the differences in expression 
levels between the two TPH isoforms (Murphy, Zhang et al. 2008). Previous 
research showed that this 41 amino acids, especially the region of amino 
acids 10-20 from TPH2 was responsible for mediating the bulk of the reduced 
expression of TPH2 (Carkaci-Salli, Flanagan et al. 2006, Murphy, Zhang et al. 
2008). Understanding the regulation of TPH2 gene expression could provide 
further insights on how the brain serotonergic system works, as the protein 
regulation of the TPH2 enzyme had been greatly studied.  
In the context of transcriptional and posttranscriptional regulation, there have 
been numerous studies characterizing genetic variants in the five prime (5’) 
and three prime (3’) untranslated regions (UTR) and introns of TPH2 gene, 
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which may regulate TPH2 expression. A recent study has found many spliced 
variants, and suggested that RNA editing of pre-mRNA is inhibitory to TPH2 
enzyme activity (Grohmann, Hammer et al. 2010) . It is therefore the focus of 
this report to look at TPH2 at the transcript level and through this, shed some 
light on its modulation. 
 
Figure 1. Schematic diagram of the major domains of an amino acid 
hydroxylase. Sequence alignment of the first 60 amino acids of human TPH2 
and corresponding residues of human TPH1 in the regulatory regions.    
 
 
1.2. TPH2 gene expression  
1.2.1. TPH2 expression during development 
Since its discovery a decade ago (Walther and Bader 2003, Walther, Peter et 
al. 2003), TPH2 has gained a lot of interest and intensive research had been 
done to investigate its expression and how it is related to psychiatric disorders. 
The human TPH2 gene is located on chromosome 12 and it is made up of 11 
exons and 10 introns with a total length of 95kb. The TPH2 protein contains 
490 amino acids with a molecular weight of 56kDa (Walther and Bader 2003, 





1.2.2. TPH2 expression in different tissues 
TPH2 was initially observed to be expressed in the brain but not in peripheral 
tissues of human and rodents (Walther and Bader 2003, Gutknecht, 
Kriegebaum et al. 2009). Analysis of post-mortem of human brain tissues had 
showed that TPH2 mRNA expression is detectable in the cortex, 
hypothalamus, thalamus, hippocampus, amygdala and cerebellum, while for 
rodents, TPH2 is the most abundant in the raphe nuclei (Luca, Likhodi et al. 
2006, Zill, Büttner et al. 2007, Gutknecht, Kriegebaum et al. 2009, Bach, 
Arango et al. 2011). 
However, TPH2 expression is not as exclusively brain-specific as previously 
thought (Walther, Peter et al. 2003, Luca, Likhodi et al. 2006, Zill, Büttner et al. 
2007, Murphy, Zhang et al. 2008, Gutknecht, Kriegebaum et al. 2009, Bach, 
Arango et al. 2011). Recent researches have shown that TPH2 can be found 
in areas of the body other than the brain. In rodents, TPH2 mRNA is found to 
be expressed in several neuroepithelial cells and enteric neurons of the gut 
(Ortíz-Alvarado, Guzmán-Quevedo et al. 2006), the retinal pigment epithelium 
(Żmijewski, Sweatman et al. 2009) and the cholangiocytes of the bile duct 
(Omenetti, Yang et al. 2011). Additionally, a high fat diet seems to induce 
TPH2 mRNA expression in the adipose tissues in mouse (Schraenen, 
Lemaire et al. 2010).  
Although the presence of TPH2 expressing outside the brain has yet to be 
shown on human, the possibilities of a non brain specific TPH2 should not be 
ruled out. Overall, these recent findings suggested that TPH2, although first 
thought to be neuronal-specific and expressed exclusively in the brain, may 




1.2.3. The diurnal nature of TPH2 expression and its regulation by 
glucocorticoids 
There has been strong evidence that support the close relationship between 
TPH2 expression and the circadian rhythm. It has been shown that TPH2 
mRNA expression fluctuates with the daily circadian rhythm. In rats, TPH2 
mRNA expression was found to peak in the night during a light/dark cycle, 
especially prior to the light-dark transition (Malek, Dardente et al. 2005).  It 
has also been shown that the diurnal pattern of TPH2 expression in male rats 
can be abolished, through the chronic administration of corticosterone, which 
can induce TPH2 mRNA expression in the dorsal raphe during the inactive 
light phase (Donner, Montoya et al. 2012). This also suggests that TPH2 
expression can be regulated by glucocorticoids (GC).  
The effect of GC on TPH2 expression and serotonin neurotransmission 
seems to be species-dependent. In rats, GC administration induced TPH2 
mRNA expression and correspondingly increased serotonin synthesis, while 
adrenalectomy decreased the brain TPH2 levels and reduced serotonin 
synthesis (Malek, Sage et al. 2007).  Additionally, a previous study revealed 
that the regulation of GC on rat TPH2 mRNA expression is tissue-specific and 
with chronic treatment of GC, an increase in the TPH mRNA level was 
observed in the pineal gland but a decrease in mRNA levels was observed in 
the brain (Clark and Russo 1997). However in mice, the administration of 
Dexamethasone, a synthetic GC that suppresses stress response (Sapolsky 
and Meaney 1986), caused a significant decrease in both the mRNA and 
protein levels of TPH2 expression in the raphe nuclei. This decrease is 
abolished by co-administration of Mifepristone (an antagonist of GC) (Clark, 
Pai et al. 2005, Clark, Flick et al. 2008). In addition, an adrenalectomy 
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abolishing GC production in mice resulted in elevated TPH2 mRNA levels, 
which was alleviated by GC replacement (Heydendael and Jacobson 2010).  
Thus, TPH2 expression fluctuates with the circadian rhythm and is regulated 
by glucocorticoids. In addition, GC regulation of TPH2 expression is species-
dependent and may be tissue-specific. These findings, along with the 
previously reported correlation between rhythmic TPH2 protein level and 
serotonin synthesis in neurons projecting to the suprachiasmatic nucleus and 
intrageniculate leaflet (Malek, Dardente et al. 2005), strongly suggest that the 
fluctuation of TPH2 gene expression is closely related to the biological clock 
and the stress response. 
 
1.2.4. The polymorphisms of human TPH2 and their association with 
mental disorders   
TPH2 has been the major candidate in numerous genetic association 
analyses of neuropsychiatric disorders, a number of which are discussed 
below.  
 
1.2.4.1. Attention Deficit Hyperactivity Disorder (ADHD) 
In a cohort of 225 children with ADHD in Germany, two single nucleotide 
polymorphisms (SNPs) (rs4570625, rs11178997) were found within the 
transcriptional control region of TPH2 gene. Familial preferential transmission 
was detected and haplotype analysis also showed an association trend 
between the regulatory region SNPs and ADHD (Walitza, Renner et al. 2005). 
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In Norway, a rare heterozygous mutation in a highly conserved residue of the 
TPH2 gene, resulting in an Arg303 to Trp (R303W, rs120074176) substitution, 
was identified in a mother and daughter pair with ADHD. The mother also had 
a history of major depression. In vitro functional expression studies showed 
that this R303W mutation caused a 95% loss of TPH2 enzymatic activity due 
to decreased solubility of the protein. It was concluded that R303W of TPH2 
gene being a loss-of-function mutation had led to a reduced serotonin 
synthesis, which may have caused an increased susceptibility to ADHD and 
major depression (McKinney, Johansson et al. 2008).  
 
1.2.4.2. Major Depressive Disorder (MDD) 
A loss-of-function mutation in TPH2 gene was identified in a cohort of 87 
patients suffering from unipolar major depression (Zhang, Gainetdinov et al. 
2005). An SNP analysis in a cohort of 87 patients with MDD and 219 controls, 
revealed that nine and three subjects, in the respective groups, carried the 
SNP that resulted in the substitution of Arg441 to His (R441H, rs120074175) 
within the catalytic domain of the protein.  
Patients with this mutation were either not or poorly responsive to SSRIs. 
Interestingly, three control subjects whom were identified to carry this 
mutation displayed clinical symptoms of comorbid conditions like anxiety and 
mild depression, even though they were not diagnosed as having MDD. 
Followup in vitro studies using cell lines showed that this R441H mutant 
caused an 80% reduction in serotonin production. This suggested that the 
presence of this loss-of-function mutation could indicate a higher susceptibility 
for certain neuropsychiatric disorders, such as major depressive disorder, due 
to the deficits in brain serotonin synthesis (Zhang, Gainetdinov et al. 2005). 
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Although, another study did not find this mutation in another cohort of similar 
ethnicity and gender distribution, they did reproduce the R441H mutant 
studies with a 91% decreased activity of TPH2 (Garriock, Allen et al. 2005).  
 
1.2.4.3. Bipolar Disorder 
In Germany and Russia, two separate cohorts of over 2000 subjects of 
patients with bipolar disorder and controls were studied. Three SNPs 
(rs11178997, rs11178998, rs7954758) and a nonsynonymous SNP, which 
resulted in a Pro206 to Ser (P206S, rs17110563) substitution in the TPH2 
gene were identified to have association with the disorder. The P206S protein 
was shown to have similar catalytic activity as the Wildtype via in vitro 
functional expression studies. P206S was also located on surface-exposed 
side chains, which may result in decreased in solubility and thermal stability 
(Cichon, Winge et al. 2008, Grigoroiu-Serbanescu, Diaconu et al. 2008, 
McKinney, Turel et al. 2009). 
 
1.3. Regulatory elements of gene expression  
As mentioned earlier, this report will focus on studying the regulation of TPH2 
at the transcript level. Understanding the fundamental and the regulatory 
elements that are involved in the expression of a gene is therefore warranted.  
 
1.3.1. Messenger ribonucleic acid (mRNA) and associated UTRs 
Messenger RNA (mRNA) belongs to a family of RNA molecules that conveys 
genetic information from the DNA to the ribosome. They specify the amino 
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acid sequence of the protein based on the genetic sequence from DNA. 
Through transcription, mRNA receives information from a section of DNA with 
the help of RNA polymerases and transcription factors. Eukaryotic mRNA, 
unlike prokaryotic mRNA, usually requires additional processing and transport. 
Precursor mRNA (pre-mRNA) is an immature single strand of messenger 
ribonucleic acid (mRNA). The DNA template is transcribed into pre-mRNA in 
the cell nucleus, which consists of the bulk of heterogeneous nuclear RNA 
(hnRNA). The pre-mRNA will then be processed to become mature mRNA, 
termed simply as mRNA.   
Eukaryotic mRNA structure is made up of 5’ cap, protein coding region, 
untranslated regions and polyA tail (Fig. 2). The 5’ cap is crucial for 
recognition and attachment of the ribosomal initiation complex and also 
protects the mRNA from nucleolytic degradation. Some parts of the coding 
regions may also serve as regulatory sequences such as exonic splicing 
enhancers or silencers during the pre-mRNA stage. 
The untranslated regions (UTRs) are the noncoding region and are divided 
into two sections, mainly the 5’ end before the start codon and the 3’ end after 
the stop codon of the coding region.  These regions are transcribed together 
with the coding region and are present in the mature mRNA. UTRs are found 
to play several roles in gene expression, affecting like mRNA localization, 
stability and also translational efficiency. 5’UTR together with 3’UTR can also 
control the stability of mRNAs through association with ribonucleases that can 
either enhance or inhibit RNA degradation. The ability to perform these 
functions depends on the specific UTR sequence, which differs between 
mRNAs (Mignone, Gissi et al. 2002).  
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The 3’UTR of an mRNA carries one or more polyadenylation sequences that 
are being cleaved or appended with a polyA tail by poly(A) polymerase. The 
polyA tail located at the 3’ end of mRNA transcript is a long sequence of 
adenine nucleotides added to the pre-mRNA to aid in export from the nucleus 
and translation, and protects the mRNA from degradation (Mignone and 
Pesole 2001).  
The 5’UTR regions on the DNA strand binds to transcriptional factors that can 
in turn mediate the binding and initiation of transcription of mRNA by RNA 
polymerase. On mRNA transcripts, several regulatory sequences may be 
found in the 5’UTR. These include riboswitches, which are protein binding 
sites that affect mRNA stability or translation (e.g. iron responsive elements), 
as well as sequences that can either promote or inhibit translation initiation. 
Additionally, introns within the 5’UTRs that have also been linked to gene 
expression regulation and mRNA export. Alternative 5’UTRs can be produce 
by alternative splicing and transcription start site variation. Diversity within the 
5’UTR of a gene enables variation in expression, and mutations to the length 
or sequence of the 5’UTR have been implicated in various human diseases 
(Davuluri, Suzuki et al. 2000). 
In eukaryotes, the length of a 5’UTR can range from 100 to thousands 
nucleotide long, while prokaryotic 5’UTRs are usually shorter than 10 
nucleotides long. Although the 5’UTR does not encode for protein, it may 
harbour motifs that are involved in mRNA stability and translational control. 
Certain short regions can still influence translation efficiency, such as the 
Kozak sequence. In addition, internal ribosome entry sites (IRES), upstream 
open reading frames (uORFs) and iron responsive elements (IRE). Mutations 




Structure of a human protein coding mRNA including 
the untranslated regions (UTRs) 
associated with diseases; SNPs within the 5’UTR have also been linked to 
individual’s drug response and diseases risk (Armengol, Gratacos et al. 2002).  
 Figure 2. Schematic diagram of the major domains of an mRNA. 
 
1.3.2. 5’UTR and TPH2  
The 5’UTR sequence variation between the TPH1 and TPH2 can be 
observed in humans, rats and mice (Stoll, Kozak et al. 1990, Boularand, 
Darmon et al. 1995, Wang, Coon et al. 1998, Chamas and Sabban 2002). 
The diversity in the 5’UTR might have functional significance for the gene 
expression of both isoforms TPHs. A publication in 2002, classified two 
isoform of the rat TPH (TPHα and TPHβ) with the characteristic of TPHβ 
marks similarity to the now TPH2, which was discovered only in 2003.They 
cloned the 5’UTR of individual rat TPH isoforms upstream of a luciferase 
reporter gene. It was observed that the TPHβ 5’UTR, which had a shorter 
half-life, could increase the luciferase activity two fold as compared to the 
TPHα 5’UTR in PC12 cells (Chamas and Sabban 2002). Their results 
indicated that selective regulation of rat TPH mRNAs with different 5’UTRs 
can play a role in differential tissue specific TPH expression. The ability of 
5’UTR to cause an increase in gene expression was unusual as 5’UTR had 
usually been associated with repressive effect.  
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Studies have also found that the TPH2 expression can be regulated by its 
5’UTR, through both transcriptional and post-transcriptional mechanisms. 
Constructs of reporter gene containing whole 5’UTR displayed low expression 
in HEK293 and RN46A cells respectively (Chen, Vallender et al. 2008).  
An asymmetric bidirectional promoter was found to be present in the 
downstream segment (+61 to +141) and an upstream segment (+8 to +53) 
exerts a strong inhibitory effect on gene expression. Such inhibitory region 
was found to be the assumed binding sites for three transcription factors 
(NRSF, IA-1 and Myf-3), only NRSF and IA-1 were identified to repress 
transcription of TPH2 gene (Breslin, Zhu et al. 2002, Patel, Bochar et al. 2007, 
Chen and Miller 2009). These results implied that the 5’UTR has an inhibitory 
effect on the post-transcriptional processing of the TPH2 mRNA. 
In this report, the differential regulation effect of the TPH2 5’UTR was shown 
in HEK cells and PC12 cells. The 5’UTR had only shown an upregulation 
effect on its homologous TPH2 gene expression only in PC12 cells. PC12 
cells are derived from rat pheochromocytoma and respond to nerve growth 
factor to differentiate to neuronal-like phenotype. PC12 has been a popular 
model for both neurosecretory and neuronal type cells and it has been used 
for studying  chemical disruption of processes associated with neuronal 
differentiation, synthesis, storage and release of neurotransmitters, function 
and regulation of ion channels and interactions of compounds with membrane 
bound receptors (Shafer and Atchison 1991).  Although belonging to different 
species, PC12 cells were used to study the effect of the TPH2 5’UTR due to 
its neuronal properties. The results showed that the 5’UTR caused an 
inhibitory effect in HEK cells, but exerted an enhancing effect on the mRNA 
and protein expression of TPH2 in PC12 cells. When expressed with a 
heterologous gene such as a reporter gene, the 5’UTR has a uniform 
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inhibitory effect on gene expression in both cell lines. The enhancing effect of 
5’UTR can only been observed when interacting with full length coding region 
of TPH2. These results suggest that there exist unknown mechanisms and 
factors like neuronal-specific factor that might act as a positive regulator 
between the 5’UTR and coding regions of TPH2 that have yet to be 
elucidated.  
 
1.4. Aims and significance 
The aim of this present study is to understand the role of 5’UTR in regulating 
the expression of TPH2 gene in HEK and PC12 cells. The specificity and 
importance of the 5’UTR will be investigated.  
We postulate that there are optimum conditions that needs to be fulfilled in 
order for 5’UTR to upregulate gene expression, and the discovery of these 
conditions can form the basis for using 5’UTR as a target for therapeutic 
intervention in the future. 
Eventually, the long-term goal is to be able to increase the brain serotonin 
levels in patients suffering from psychiatric disorders, through regulating 
hTPH2 gene expression. The appeal of targeting 5’UTR lies in its specificity in 
regulating TPH2, and this higher specificity would in turn minimize side effects 




2. Materials and Methods 
 
2.1. Molecular work 
2.1.1. Construction of 5U-TPH2-HA  
 
The full-length human TPH2 gene (Ensembl: ENST00000333850) contains 
11 exons and spans 95kb on Chromosome 12q21.1. Its mRNA 
(NM_173353.3) coding sequence consisting of 1472 nucleotides and 490 
amino acids were cloned into a pcDNA3.1 vector (Invitrogen, Life 
Technologies), downstream of a CMV promoter. All constructs in this study 
were cloned into a pcDNA3.1 vector (p3), unless otherwise stated. For ease 
of detection of the protein expression in Western blot, a hemagglutinin (HA) 
epitope was tagged to the C-terminal of TPH2 (TPH2-HA) (Fig. 3A). The 
genomic DNA for the 5’UTR and the TPH2-HA was a gift from Dr. Zhang. 
Primers were designed and used to amplify the 5’UTR, before the fragment 
was cloned into the 5’ end of the TPH2-HA (Fig. 3B).  
A 256bp fragment was amplified from genomic DNA using 5U/N-F (5’-
AAAAAAGCTTCATTGCTCTTCAGCACCAG-3’) and 5U/N-R (5’-
TGTTGAGCTGCCAAGTAGCTGATGC-3’) primers and from TPH2-HA using 
5U/C-F (5’-AGAGCATCAGCTACTTGGCAGCTCAAC-3’) and Ner1-R (5’-
ATCCTCTAGCTCTTCTTCCTCTGTCCAAA-3’). The PCR products were 
mixed and amplified using 5U/N-F and Ner1-R. Following sequential digestion 
by HindIII and EcoRI, the final PCR product was subcloned into TPH2-HA 
using LigaFastTM Rapid DNA Ligation System (Promega, USA) and the 
resultant construct was transformed into DH10β competent cells (Inoue, 
Nojima et al. 1990). Screening using p3-F (5’-
TAGGCGTGTACGGTGGGAGGTCTATATAA -3’) and p3-R (5’-
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AAACAACAGATGGCTGGCAACTAGAAGGCA-3’) was done in 10µl reaction 
(2.5µl of 4x Taq buffer, 0.5U GoTaq® Flexi DNA Polymerase, 0.2mM of 
deoxyribonucleotide triphosphate (dNTPs), 0.2µM of each primer, and topped 
up with diethylpyrocarbonate (DEPC)-treated water) (Promega, USA). Mini-
prep and Maxi-prep were done using QIAprep Spin Miniprep Kit (Qiagen, 
Germany) and NucleoBond® Xtra Maxi (Macherey-Nagel, Germany), 
respectively, for the selected colonies (Fig. 4A). All constructs in this report 
were verified by sequencing (1st Base, Singapore or Macrogen, Korea). 
 
2.1.2. Construction of 5U-Rluc-HA and 5U-EGFP 
The 5’UTR from the 5U-TPH2-HA was digested with HindIII and BamHI and 
subsequently subcloned into RLuc-HA and EGFP vectors (Gifts from Dr. 
Zhang) (Fig. 5A, B). The resultant constructs, 5U-RLuc-HA and 5U-EGFP 
were used for transformation into DH10β competent cells. PCR screening 
was carried out using p3-F and p3-R, and selected clones were subjected to 
Maxi-prep to increase quantities for transfection.  
 
2.1.3. Construction of the pTight constructs 
An inducible expression system was needed to allow us to tightly control gene 
expression. Thus, the tetracycline-inducible expression system (Tet-On) and 
pTRE-Tight vector (pTight, pT) (Clontech, USA) were chosen for this study.  
Using the pT-HAYFP as backbone, the TPH2-HA and 5U-TPH2-HA 
fragments were subcloned into pT-HAYFP. In order to visualize the gene 
induction, the yellow fluorescent protein (YFP) was fused to the HA tag and 
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could be detected using a fluorescence microscope. The resultant constructs 
were named pT-TPH2-HAYFP and pT-5U-TPH2-HAYFP (Fig. 6A). 
The pT-EGFP was made by subcloning from EGFP vector using primers, 
GFP01-F (5’- AAAAAAGCTTAGGATCCATGGTGAGCAAG -3’) and p3-R. pT-
5U-EGFP was subcloned from p3 5U-EGFP using restriction enzyme. For 
constructs with the Methionine (Met) removed, it is denoted with a (-M). pT-(-
M)EGFP and pT-5U-(-M)EGFP were subcloned from pT-EGFP and pT-5U-
EGFP using primers GFP5U-F (5’-AAATGGATCCTGAGCAAGGGCGAGGA-
3’) and p3-R, respectively. All subcloning into the pTight vectors were done 
using restriction enzyme HindIII and Xbal (Fig. 6B). 
 
2.1.4. Construction of truncated 5’UTR constructs 
Truncated 5’UTR was generated using PCR, with primers that contain 
restricted enzyme sites incorporated at the 5’ end. Two 5’UTR fragments, +36 
to +141 (F:5’-AAAAGCTTCAAGCAGGCAGCTGATCGCA-3’) and +86 to 
+141 (F:5’-AAAAGCTTTGCTACTGCCCCT-3’) were primed with p3-R using 
5U-TPH2-HA and 5U-RLuc-HA as template. These truncated 5’UTR 
fragments were then subcloned into the TPH2-HA and RLuc-HA constructs 
using restriction enzymes, HindIII and Xbal. The resultant constructs were 
named 5U(36)-TPH2-HA, 5U(86)-TPH2-HA, 5U(36)-RLuc-HA and 5U(86)-
RLuc-HA (Fig.7A,C). 
 
2.1.5. Construction of truncated TPH2 constructs 
Using TPH2-HA and 5U-TPH2-HA as templates, with p3-F and reverse 
primers at the 150aa (5’- TTTTCTTAAGATCCTCTAGCTCTTCTTCCT -3’), 
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300aa (5’-TTTTCTTAAGCTGGGTACAGTGGAACACT -3’) and 490aa (5’-
TTTTCTTAAGAATCCCCAGATATTGGTTC -3’) of the full-length TPH2; the 
fragments were subcloned into RLuc-HA using restriction enzymes, HindIII 
and AFlII. The resultant constructs were named N150 RLuc-HA, N300 RLuc-
HA, TPH2 RLuc-HA, with 5U would indicate the presence of 5’UTR at the 5’ 
end (Fig. 8A).  
 
2.2. Culture of cells and transfection 
2.2.1. Cell culture and transient transfection 
Human Embryonic Kidney 293 (HEK) cells were grown in Gibco’s minimal 
essential medium (MEM) with 10% (v/v) fetal bovine serum (FBS) (Hyclone, 
UT, USA) and a 50µg/ml gentamicin (Gibco®) solution. Cells were plated at 
the density of 1.5 x 106 cells/dish and incubated overnight in 100mm dishes; 
the medium was changed at least 2hrs prior to transfection and at 24hrs post-
transfection. Cells were transiently transfected by calcium phosphate 
treatment; 2µg of DNA was first mixed with 450µl of filtered H2O followed by 
50µl of 2.5M CaCl2  and 500µl of 2x HBS buffer (pH7.1) (2M NaCl, 0.5M 
HEPES(pH7.0), 1M Na2HPO4). The mixture was incubated for 15mins and 
added to the cell culture gently with swirling, followed by incubation in 37°C 
with 5% CO2 incubator. All chemicals and reagents used in this report were 
purchased from Sigma-Aldrich unless otherwise stated.        
Rat adrenal medulla pheochromocytoma (PC12) cells were cultured in DMEM 
medium (Sigma-Aldrich, MO,USA), pH7.3, supplemented with 5% Iron-
Supplemented Bovine Calf Serum, US Origin (Hyclone, UT, USA), 10% horse 
serum, New Zealand origin (Gibco®), 0.1mM MEM Non-Essential Amino 
Acids (Gibco®) and 1mM MEM Sodium Pyruvate (Gibco®).  Cells were 
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plated at a density of 6  x 106 cells/dish and incubated overnight in 100mm 
dishes; the medium was changed at least 2hrs prior to transfection and at 
24hrs post-transfection. PC12 cells were transfected with 2µg of DNA using 
Lipofectamine™ 2000 reagent (Invitrogen™, CA, USA), according to the 
manufacturer’s protocol. The mixture was added to the cell culture gently, 
swirled to mix and incubated in 37°C with 10% CO2 incubator. 
The cells were harvested at 48hrs post-transfection, by washing once with 
5ml of ice-cold 1x phosphate-buffered saline (PBS). The cells were then 
harvested in 5ml of cell detachment buffer (20mM Tris (pH8.0), 150mM NaCl, 
1mM EDTA, 1mM ethylene glycol tetra acetic acid (pH8.0) (EGTA)) and 
centrifuged at 3000rpm for 15mins at 4°C. The resulting cell pellet was 
resuspended in 1ml of ice-cold 1x PBS and transferred to two microcentrifuge 
tubes and centrifuged at 3000rpm for 15mins at 4°C. The supernatant was 
discarded and the cell pellets were snap-frozen with liquid nitrogen and stored 
in -80°C for future use.  
 
2.2.2. Generation of PC12 cell lines stably expressing transactivator 
protein (rtTA) 
The rtTA from the pTight vector was subcloned into an IRES BSD plasmid. 
PC12 cells were transfected by electroporation (Bio-rad, Gene Pulser Xcell™ 
Total System, Hercules, CA, USA) (at 300 voltage (V) and 1000 capacitance 
(µF)) with 5µg rtTA-Ires-Bsd plasmid. The medium of the transfected cells 
were changed 24hrs after transfection. Stable PC12 cell lines expressing rtTA 
(PC12-rtTA) were selected in the presence of 15µg/ml of Blasticidin (BSD) in 
DMEM medium. The PC12-rtTA cells were made so that cells would be 
expressing the rtTA, which requires tetracycline for DNA binding and hence 
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transcription. PC12 cells are sensitive to transfection, thus with PC12-rtTA 
cell lines, the number of transfection can be reduced. 
 
2.2.3. Tetracycline-Inducible Expression System (Tet-On) 
HEK cells were seeded at the density of 1 x 106 cells/dish in a 100mm dish, 
24hrs prior to transfection. A stepwise transfection was carried out. Firstly, 
5µg of the rtTA was transfected using the calcium phosphate method (as 
mentioned in section 2.2.1) and incubated overnight, and the medium was 
changed after 18hrs. At 24hrs post transfection, 2µg of pTight constructs with 
1µg of rtTA were co-transfected using Lipofectamine™ 2000 and medium 
was changed after 18hrs.  After 65hrs from the first transfection, construct 
expression was induced using 0.5µg/ml Doxycycline for 4hrs, before the cells 
were pelleted and stored in -80°C. 
PC12-rtTA cells were plated at the density of 6  x 106 cells/dish and incubated 
overnight in 100mm dishes; the medium was changed at least 2hrs prior to 
transfection and at 24hrs post-transfection. PC12 cells were transfected with 
2µg of pTight constructs with 1µg of rtTA using Lipofectamine™ 2000, 
following the manufacturer’sprotocol. The mixture was added to the cell 
culture gently, swirled to mix and incubated in 37°C with 10% CO2 incubator. 
At 48hrs post transfection, cells were subjected to 6hrs with 0.5µg/ml 
Doxycycline treatment before the cells were pelleted and stored in -80°C. 
 
2.3. Protein extraction and Western blot 
The cell pellets were lysed in 100µl of ice-cold lysis buffer (20mM Tris (pH8.0), 
150mM NaCl, 1mM EDTA, 1mM EGTA, 1% Triton X-100) with 8µl of 25x 
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CompleteTM protease inhibitor cocktail (Roche, USA) and 5µl of 100mM 
phenylmethanesulphonylfluoride (PMSF). The lysate was kept on ice for 
15mins and centrifuged at 13000rpm for 10mins at 4°C before the resulting 
supernatant was collected.  The protein concentration was determined 
according to the Lowry method using BioRad’s DC Protein Assay Kit. Equal 
amounts of 2x SDS buffer (100µl of 4x SDS buffer (250mM Tris-HCl, 8% SDS, 
40% Glycerol, Bromophenol blue), 200mM dithiothreitol (DTT), 10% of β-
mercaptoethanol) was added to the protein lysate. The mixture was incubated 
at 55°C for 10mins prior to separation on a 10% denaturing SDS-PAGE (Mini-
PROTEAN® Tetra cell, Bio-rad) at 100V for 90mins. Optimization with various 
protein amounts and antibodies concentration were carried and loading 
amount was finalized at 20µg and 50µg of HEK and PC12 cells lysate 
respectively throughout this report. Proteins were electrophoretically 
transferred onto 0.45mm nitrocellulose membranes (Mini Trans-Blot®, Bio-rad) 
at 100V for 90mins at 4°C. Membranes were then stained with Ponceau S 
and destained with 7% acetic acid (Merck Millipore, Germany), to visualize 
the separation and transfer efficiency. The membranes were blocked with 5% 
milk in 1x PBST (1xPBS with 0.05% Tween-20) for 1hr. HA-tagged proteins 
were detected using anti-HA antibody (Covance, USA) diluted at 1:20,000; 
and anti-Actin (Millipore, USA) diluted 1:20,000 was used as loading control. 
All primary antibodies were incubated overnight at 4°C. Membranes were 
then washed for  30mins (3x 10mins) with 1x PBST, followed by incubation 
for 1hr with goat anti-Mouse IgG (H+L) secondary antibody, horseradish 
peroxidase conjugate (Pierce, USA). Blots were detected using the 
SuperSignal® West Pico Chemiluminescence Kit (Pierce, USA) and detected 
on X-Ray film (GE Healthcare, UK). To prevent over saturation, multiple 
exposure (10-30s) were taken and compared.  Films were scanned using 
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ImageQuant ET-RCL (GE Healthcare, UK) and densitometric analysis was 
performed using Image J (NIH, Version 1.47). 
 
2.4. RNA extraction 
Total RNA from cell pellets were obtained using TRI Reagent® RNA Isolation 
Reagent. One millilitre of TRI Reagent was added to the cell pellet and 
homogenized on ice using cell pellet homogenizer (Kontes, Fisher Scientific). 
The homogenate was then incubated at room temperature (RT) for 10mins. 
400µl of 1-bromo-3-chloropropane was added before the mixture was 
vortexed vigorously and then incubated at RT for 10mins. Centrifugation at 
13000rpm, 4°C, for 15mins was performed to separate the mixture into 2 
phases: the RNA-containing aqueous phase and the organic phase 
containing DNA and protein. The aqueous phase was carefully aspirated and 
transferred into a fresh tube containing 400µl of 100% isopropanol (Merck 
Millipore, Germany), before being mixed gently and centrifuged for 10mins at 
13000rpm, 4°C, to pellet the RNA. The pellet was washed once with 75% 
ethanol (Merck Millipore, Germany) in DEPC water, centrifuged for 5mins at 
9000rpm, 4°C, then air-dried for 15mins. Pellets were finally reconstituted in 
35-60µl of DEPC water depending on pellet size, then heated at 55°C for 
10mins to facilitate dissolution. RNA quantification was performed to check for 
yield and purity and before storing at -80°C.  
 
2.5. Quantitative PCR and semi-quantitative PCR 
ProtoScript® M-MuLV First Strand cDNA Synthesis Kit (New England Biolabs, 
MA, USA) was used to obtain first strand complementary DNA (cDNA) from 
1µg of DNase 1 treated RNA. The total RNA was treated with DNase 1 (New 
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England Biolabs, MA, USA). 1µl of DNase 1 buffer and DNase 1 was added 
to the given RNA in DEPC water and incubated at RT for 10mins. The 
reaction was stopped by incubation at 70°C for 5mins.  
Real-time quantitative PCR (qPCR) was performed using EXPRESS SYBR® 
GreenER™ qPCR Supermix Universal (Invitrogen™, CA, USA ) with forward 
and reverse primers for specific genes (Table 1) at the following conditions: 
denaturation at 95°C for 3mins followed by 40 cycles of amplification at 95°C 
for 10s, 58°C for 20s and 72°C for 30s. Gene expression was carried out in a 
single reaction and was normalized to a separation reaction looking at the 
housekeeping gene, Glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
A series of template dilutions were carried to ensure that the Ct (threshold 
cycle) falls between 20 to 30 cycles.   
Semi-quantitative PCR (semi-qPCR) was performed using 0.5U GoTaq® 
Flexi DNA Polymerase, 0.2mM deoxynucleotides (dNTPs), 0.2µM each of 
forward primer and reverse primer and amplification at the following 
conditions: 2mins denaturation at 94°C, followed by 25-35 cycles of 30s 
denaturation at 94°C, 30s annealing at 55-60°C and 60s extension at 72°C, 
with a final extension of 30s at 72°C. Gene expression was normalized to 
GAPDH. Amplification products were separated by electrophoresis on 1.2% 
to 1.5% agarose gels (1st base, Singapore) and visualized by ethidium 
bromide (Bio-rad) staining.  
 
2.6. Renilla Luciferase - Bioluminescence Assay (RLuc assay) 
At 48hrs post-transfection, transfected PC12 and HEK cells were detached 
and seeded at 1x105cells/well and 5x104cells/well respectively, on to a 
50µg/ml poly-l-lysine coated 96 well plates. Cells were seeded in duplicate. 
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After overnight incubation, culture medium was removed and cells were 
washed once with PBS. For cells transfected pTight constructs, 0.5µg/ml 
Doxycycline (Clontech, CA, USA) was added for 4hrs and 6hrs in HEK and 
PC12 cells respectively, prior to PBS wash. 100µl of 2µg/ml Coelenterazine-h 
(Promega, WI, USA) in PBS (Hyclone) was added into each well just prior to 
detection on a microplate reader (Tecan infinite®200 PRO series). Readings 
were normalized to cells transfected with pairing constructs without the 5’UTR. 
The remaining trypsinized HEK and PC12 cells from the transfected plates 
were then seeded at the density of 2.5x106 and 1x107 cells per 100mm dish 
respectively and incubate overnight. Cells were pelleted immediately after 
4hrs and 6hrs incubation with 0.5µg/ml Doxycycline in HEK and PC12 cells 
respectively. Cells were washed once with PBS (pH 8.0), and detached in 3ml 
PBS. Detached cells were split into 2 tubes for centrifugation at 3000rpm for 
15mins. After centrifugation, the supernatant were removed, and the pellets 
were snap-frozen in liquid nitrogen and stored in -80°C freezer prior to use.  
 
2.7. Statistical Analysis 
All statistical analysis and graphical representation were performed using 
Excel 2007 (Microsoft) and Prism (Version 5). Statistical analysis on the 
interactions between the constructs and cell types and if the cell type and 
constructs alone would affect the results were performed by an analysis of 
variance (ANOVA) and comparison of gene expression between constructs of 
same cell type were analyzed by paired two-tailed t-tests. Data was 
expressed as means ± standard error of mean (SEM), and p < 0.05 was 





Figure 3. Vector map and constructs used. (A) A vector map illustration of 
the restriction sites where the gene of interests, “X”, are inserted. “X” refers to 
TPH2, RLuc and eGFP gene where in the latter the HA gene is absent. The 
5’UTR is inserted upstream of “X” using HindIII and BamHI restriction sites. (B) 
Schematic illustration of the construction of 5U-TPH2-HA. The 5’UTR PCR 
amplicon was then subcloned into TPH2-HA using restriction enzymes, 


























































3.1. The effect of the 5’UTR on TPH2 expression is cell-type specific 
The constructs TPH2-HA and 5U-TPH2-HA were transiently transfected into 
HEK and PC12 cells, with assumption made that the transfection efficiency 
was the same within each cell type. Western Blot analysis of HEK cells 
transfected with 5U-TPH2-HA showed lower HA expression as compared to 
that of TPH2-HA transfection (Fig. 4B, left panel). In contrast, transfection of 
PC12 cells with 5U-TPH2-HA resulted higher HA expression as compared to 
that of TPH2-HA transfection (Fig. 4B, right panel). This suggests that the 
5’UTR decreases TPH2 protein level in HEK cells, but increases TPH2 
protein levels in PC12 cells. 
To clarify whether transcriptional or post-transcriptional mechanisms were 
involved in the 5’UTR regulation of TPH2 gene expression, the mRNA 
abundance were also quantified using qPCR (Fig. 4C). GAPDH was used as 
a loading control, and the TPH2 mRNA abundance of 5U-TPH2-HA 
transfected cells were normalized to that of TPH2-HA transfected cells. In 
HEK cells, transfection with 5U-TPH2-HA caused the mRNA abundance  to 
decrease to 44.0% (±4.53, n=3), whereas in PC12 cells, transfection with 5U-
TPH2-HA resulted in a 1.78 (±0.01, n=5) fold increase as compared to the 
TPH2-HA transfected cells. As such, the TPH2 mRNA abundance 
corresponded with the protein level, thus strengthening the hypothesis that 
there is a different effect of 5’ UTR on TPH2 gene expression between the 







Figure 4. The effect of the 5’UTR of TPH2 gene expression is cell-type 
specific. (A) Graphical representation of the constructs cloned into a 
pcDNA3.1 vector. (B) Representative immunoblot of TPH2-HA and 5U-TPH2-
HA expression in HEK and PC12 cells. In HEK cells, the HA protein 
expression in cells transfected with 5U-TPH2-HA was lower than TPH2-HA 
transfected cells. In PC12 cells, 5U-TPH2-HA transfected cells expressed 
higher HA protein level than TPH2-HA transfected cells. (C) The mRNA 
abundance of 5U-TPH2-HA tranfected cells as compared to TPH2-HA 
transfected cells were decreased by 44.0% (±4.53, n=3) in HEK cells, 
whereas a  1.78 (±0.01, n=5) fold increase were observed in PC12 cells. The 
interaction among the constructs and cell type, and the constructs and cell 
type independently also has significant effect on the results as analyzed with 
two-way ANOVA (p<0.0001). Error bars, ±SEM. *p <0.05, **p <0.01 





3.2. 5’UTR causes a decrease in heterologous gene expression 
To investigate the specificity of 5’UTR in regulating TPH2 gene expression, 
sequence encoding the 5’UTR was cloned upstream of two heterologous 
genes, namely RLuc and EGFP, to assess the effect of 5’UTR on their 
expression (Fig. 5A, B). These two genes, RLuc and EGFP, were selected 
because they are frequently used as reporters to study transcriptional 
regulation and gene expression. mRNA abundance and protein expression of 
RLuc-HA and EGFP in the transiently transfected HEK and PC12 cells were 
analyzed by semi-qPCR and Western Blot respectively. 
A quick approach, semi-qPCR, to look at the mRNA abundance of gene in 
transfected cells were carried out. This technique captured the amplified pcr 
product just before it becomes saturated, usually by limiting the number of 
cycles of amplification. The differences in band intensity after normalization to 
a housekeeping gene indicate the differences in mRNA abundance of the 
targeted gene. In the case where significant differences were already 
observed using this method, qPCR analysis then were not be carried out.  
Semi-qPCR densitometry analysis showed that the 5’UTR caused the mRNA 
abundance of RLuc gene to decrease to 52.7% (±1.82, n=4) and 56.7% 
(±1.82, n=6) as compared to the RLuc-HA in the HEK and PC12 cells, 
respectively (Fig. 5C). The same inhibitory effect was also observed in the 
bioluminescence assay, where it was observed that with 5’UTR, RLuc activity 
decreased to 56.2% (±1.39, n=5) and 64.5% (±1.36, n=6) as compared to the 
RLuc-HA in the HEK and PC12 cells, respectively (Fig. 5E).  
qPCR analysis of the EGFP mRNA showed that in the presence of an 
upstream 5’UTR, the mRNA abundance of EGFP decreased to 12.3% (±1.31, 
n=6) as compared to the control (Fig. 5D). The same inhibitory effect was 
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also observed in the EGFP protein expression. As compared to control, 
densitometric analysis showed that the presence of 5’UTR caused the EGFP 
protein level to decrease to 58.7% (±2.46, n=4) and 59.3% (±2.11, n=6) as 
compared to the control, EGFP, in the HEK and PC12 cells, respectively (Fig. 
5F). 
In summary, when 5’UTR was inserted upstream of the two heterologous 
genes in HEK cells, a decrease in protein levels and mRNA abundance were 
observed in the RLuc and EGFP constructs, similar to that of the TPH2 
expression when 5’UTR is inserted upstream. This suggested that the 5’UTR 
of TPH2 exerted an inhibitory effect when attached upstream of any gene in 
HEK cells. However, in the case of PC12 cells, an upregulation of the protein 
levels and mRNA abundance were observed only when the 5’UTR was 
attached to TPH2 and not when it was attached to heterologous genes, 
suggesting that there is a specificity of 5’UTR in the upregulation of TPH2 





Figure 5. The 5’UTR causes a decrease in heterologous gene expression. 
(A, B) Graphical representation of the constructs cloned into a pcDNA3.1 
vector. The plasmids were used for transfection and expression in HEK and 
PC12 cells were analyzed. (C) The effect of 5’UTR on RLuc mRNA 
abundance was analysed using semi-qPCR and densitometry analysis. The 
5’UTR caused the mRNA abundance to decrease to 52.7% (±1.82, n=4) and 
56.7% (±1.82, n=6) as compared to the RLuc-HA in the HEK and PC12 cells, 
respectively. A representative DNA gel image of the semi-qPCR was shown 
below. The interaction among the constructs and cell type (p=0.755), and the 
cell type alone (p=0.755) have no significant effect on the results, only the 
construct was found to has significant effect on the result as analyzed with 
two-way ANOVA (p<0.01). (D) qPCR analysis showed that the 5’UTR caused 
the mRNA abundance of EGFP expression to decrease to 12.3% (±1.31, n=6) 
as compared to the p3 EGFP. A semi-qPCR representative DNA gel image 
was shown in the insert. (E) Bioluminescence assay showed that with 5’UTR, 
RLuc activity decreased to 56.2% (±1.39, n=5) and 64.5% (±1.36, n=6) as 
compared to the RLuc-HA in the HEK and PC12 cells, respectively. (F) The 
protein level of the 5U-EGFP was decreased to 58.7% (±2.46, n=4) and 59.3% 
(±2.11, n=6) as compared to the p3 EGFP in the HEK and PC12 cells, 
respectively. A representative immunoblot was shown below. The constructs 
(p<0.005) and the cell type (p<0.005), independently was found to has 
significant effect on the result in both (E) and (F), as shown with two-way 
ANOVA. Error bars, ±SEM. *p<0.05, **p<0.01, ***p<0.001 compared between 
the indicated constructs.  
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3.3. 5’UTR affects gene expression on a transcriptional level 
To further investigate the effect of 5’UTR on TPH2 gene expression, and 
whether the regulation is at the transcriptional level, two more sets of 
constructs were made using the pTight vector. The pTight vector was chosen 
to allow control of the gene expression through an inducible system. This 
system enables a uniform switching on of the gene transcription and enables 
the amount of transcribed mRNA to be quantified. Gene expression was 
induced by adding Doxycyline, a Tetracycline derivative.   
The first set of experiments looked into the expression system of pT-TPH2-
HAYFP and how 5’UTR affected the gene expression in a tightly regulated 
environment (Fig. 6A). A yellow fluorescent protein (YFP) was attached to the 
TPH2-HA gene to provide a visualisable expression product of the TPH2 
gene. It was expected for the YFP expression to correspond with the TPH2 
expression as they were transcribed together. For quantification purposes, 
cDNA were derived from mRNA of transfected cells and qPCR analysis was 
carried out. In HEK cells, the presence of the 5’UTR caused the mRNA 
abundance of TPH2 and YFP to decrease to 55.3% (±2.62, n=7) and 57.5% 
(±2.82, n=7) as compared to the control (Fig. 6C, left). In PC12 cells, the 
presence of 5’UTR resulted in a 1.81 (±0.14, n=3) fold and 1.38 (±0.05, n=3) 
fold increase in the mRNA abundance of the TPH2 and YFP, respectively (Fig. 
6C, right).  
The qPCR analysis of transfected HEK cells showed that the 5’UTR caused 
the mRNA abundance of EGFP to decrease to 36.0% (±2.38, n=5) as 
compared to pT-EGFP (Fig. 6D). To determine whether 5’UTR regulates 
transcription or translation, we examined how 5’UTR affects the gene 
expression in the presence or absence of a start codon (AUG) that codes for 
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Methionine (Met), the first amino acid of the EGFP gene using the inducible 
pTight system (Fig. 6B). By removing the start codon, translation could not 
occur; therefore any observed changes in gene expression levels would be 
due to the effect of 5’UTR on transcription. When the Met was removed, the 
mRNA expression of pT-(-M)EGFP increased by 1.49 (±0.24, n=5) fold as 
compared to pT-EGFP construct (Fig. 6D). This was expected as the mRNA 
could not be translated due to the lack of a start codon, and thus accumulated 
within the cells. These constructs were only tested on HEK cells, because it 
had been established in the prior section (Subpart 3.2) that the presence of 
the 5’UTR reduces the expression of heterologous genes in both cell lines 
(Fig. 5). As such it would stand to reason that the results observed in the HEK 
cells were applicable to the PC12 cells. Interestingly, the 5’UTR also caused 
the mRNA abundance of pT-5U-(-M)EGFP to decrease to 35.2% (±5.9, n=5) 
as compared to pT-(-M)EGFP. The inhibitory effect of 5’UTR on pT-5U-(-
M)EGFP transfected cells suggested that the regulation of gene expression 
by the 5’UTR occurred at a transcriptional level instead of translational level, 






Figure 6. 5’UTR affects gene expression on a transcriptional level. (A, B) 
Graphical representation of the constructs cloned into a pTight vector. (C) 
qPCR analysis of transfected HEK cells showed that the 5’UTR caused the 
mRNA abundance of TPH2 and YFP to decrease to 55.3% (±2.62, n=7) and 
57.5% (±2.82, n=7) as compared to the pT-TPH2-HAYFP. In PC12 cells, the 
5’UTR resulted in a 1.81 (±0.14, n=3) fold and 1.38 (±0.05, n=3) fold increase 
in the mRNA abundance of the TPH2 and YFP, respectively. The interaction 
among the constructs and cell type (p<0.005), and the constructs (p<0.0001) 
and cell type (p=0.05) independently also has significant effect on the results 
as analyzed with two-way ANOVA. (D) qPCR analysis of transfected HEK 
cells showed that the 5’UTR caused the mRNA abundance of pT-5U-eGFP to 
decrease to 36.0% (±2.38, n=5) , while pT-(-M)EGFP resulted in a 1.49 
(±0.24, n=5) fold increased as compared to the pT-EGFP. The 5’UTR caused 
the EGFP mRNA abundance of pT-5U-(-M)EGFP to decrease to 35.2% (±5.9, 
n=5) as compared to pT-(-M)EGFP. There is significant differences among 
the groups as analyzed with one-way ANOVA (p<0.05). Error bars, ±SEM. 





3.4. Full length 5’UTR is needed for the greatest effect on TPH2 
expression  
The length of the 5’UTR of the TPH2 in human, rats and mice ranges from 
117 to 141 nucleotides, they were considered short when compared to the 
typical length of 100 to several thousand in other Eukaryotes. The 5’UTR of 
TPH2 was truncated and its effect on both homologous (TPH2) and 
heterologous (RLuc) gene expression were investigated. 
The 5’UTR of TPH2 was truncated and left with either +36 to +141 or +86 to 
+141 amino acids. These truncated forms of 5’UTR were attached to TPH2-
HA (5U(36)-TPH2-HA and  5U(86)-TPH2-HA) and RLuc-HA (5U(36)-RLuc-
HA and 5U(86)-RLuc-HA) and effect of the truncation was determined by 
measuring the protein expression levels of TPH2-HA using Western blot and 
RLuc-HA using bioluminescence assay (Fig. 7A and C).  
In PC12 cells, both the full length and truncated forms of 5’ UTR resulted in 
an increase in TPH2 protein expression. 5U-TPH2-HA transfected PC12 cells 
resulted in the highest increase of 14.7 (±0.21, n=6) fold, as compared to 
TPH2-HA. Whereas PC12 cells transfected with the truncated forms of 
5U(36)-TPH2-HA and  5U(86)-TPH2-HA also had increased protein 
expression of 4.5 (±0.30, n=6)  and 6.4 (±0.41, n=6) fold, respectively (Fig. 
7B). Among the different forms of 5’UTR, the increase in TPH2 expression 
levels from the full length 5’UTR was significantly higher than either of the 
truncated forms. 
Conversely, for RLuc expression, the presence of the full length 5’UTR and 
both truncated forms of 5’UTR reduced its activity in both transfected HEK 
and PC12 cells in the bioluminescence assay. The full length 5’UTR caused 
the luciferase activity to decrease to 56.2% (±1.39, n=4) and 64.5% (±1.36, 
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n=4) as compared to the RLuc-HA transfected HEK and PC12 cells, 
respectively (Fig. 7D), which is in line with our earlier observation that the 
presence of the 5’UTR reduced the expression of heterologous genes (Fig. 
5C and E). The truncated forms of 5’UTR also showed a trend towards 
downregulation of RLuc expression though the effects were not significantly 





Figure 7. Full length 5’UTR is needed for the greatest effect on TPH2 
expression. (A, C) Graphical representation of the constructs with a series of 
truncated 5’UTR cloned into a pcDNA3.1 vector. (B) The attachment of 5U, 
5U(36) and 5U(86) to TPH2-HA resulted in a 14.7 (±0.21, n=6), 4.5 (±0.30, 
n=6) and 6.4 (±0.41, n=6) fold increase in protein expression as compared to 
the TPH2-HA control. There is significant differences among the groups as 
analyzed with one-way ANOVA (p<0.0001). (D) Bioluminescence assay 
showed that 5’UTR caused RLuc activity to decrease to 56.2% (±1.39, n=4) 
and 64.5% (±1.36, n=4) as compared to the Rluc-HA in HEK and PC12 cells, 
respectively. The 5U(36) and 5U(86) attached RLuc-HA expressed activity at 
88.9% (±1.79, n=4) and 76.6% (±1.92, n=4) in HEK cells, while in PC12 cells 
they expresses at 66.5% (±2.33, n=4) and 80.3% (±1.85, n=4). The constructs 
(p<0.05) and the cell type (p<0.01), independently was found to has 
significant effect on the result as shown with two-way ANOVA. Error bars, 







3.5. Full length 5’UTR only upregulates expression when attached to 
full length homologous TPH2 gene in PC12 cells 
Our results thus far indicated that the presence of 5’UTR upregulates 
expression levels of only its homologous gene TPH2 in PC12 cells. Therefore, 
experiments were carried out to investigate if a particular region of the TPH2 
gene is needed for interaction with the 5’UTR to regulate expression. Two 
truncated forms of the TPH2 coding region, N150 (1-150aa) and N300 (1-
300aa) and the full length TPH2 were each attached to RLuc-HA and 
transfected, with or without the 5’UTR, into HEK and PC12 cells (Fig. 8A). 
The presence of the 5’UTR downregulate protein level of the N150-RLuc-HA 
and N300-RLuc-HA in HEK cells to 66.2% (±2.38, n=4) and 67.5% (±2.91, 
n=4) of the RLuc-HA control, respectively; and caused the full length TPH2-
RLuc-HA to have protein levels of about 64.2% (±2.16, n=4) as compared to 
the control (Fig. 8B). In PC12 cells, the presence of the 5’UTR did not 
significantly affect the expression levels of the truncated TPH2 constructs, 
N150 and N300, relative to their respective controls that did not have the 
5’UTR attached (Fig. 8C). However, the 5’UTR resulted in a 1.18 (±0.02, n=3) 
fold increase in the protein level when it was attached to full length TPH2. 
Another two truncated TPH2 constructs (-N150 and 151-300aa) were also 
made (Fig. 8A), and these constructs were found that the presence of  5’UTR 
resulted in similar regulation of expression patterns as the N150 and N300 
truncated constructs in the HEK and PC12 cell lines (data not shown). 
Overall, the results from this report suggest that the role of 5’UTR in 
regulating the TPH2 gene expression differs between cell lines. The 5’UTR 
caused a decrease in TPH2 expression levels in transfected HEK cells but an 
increase in transfected PC12 cells. Secondly, the role of 5’UTR in 
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upregulation of TPH2 in PC12 cells is specific, as a decrease was observed 
in the mRNA abundance and protein levels of heterologous genes regardless 
of cell type. Next, using an inducible expression system and qPCR, the 
regulatory effects of 5’UTR was shown to be on a transcriptional level. Finally, 
the results showed that full length 5’UTR is needed for the greatest 
enhancement effect on TPH2 expression, and only upregulate expression 
when attached to the full length, but not truncated forms of the homologous 









Figure 8. Full length 5’UTR only upregulate expression when attached to 
full length homologous TPH2 gene in PC12 cells.  (A) Graphical 
representation of the constructs with a series of truncated TPH2 made that 
were attached to RLuc-HA and cloned into a pcDNA3.1 vector. (B) Using 
Western blot for HA protein; in HEK cells, the presence of 5’UTR caused the 
protein expression of N150, N300 and full length TPH2 attached RLuc-HA to 
decrease to 66.2% (±2.38, n=4), 67.5% (±2.91, n=4) and 64.2% (±2.16, n=4)  
as compared to the individual constructs without the 5’UTR. (C) Using 
Western blot for HA protein; in PC12 cells, the 5’UTR resulted in a 1.18 
(±0.02, n=3) fold increase in the protein expression of TPH2 attached RLuc-
HA, while N150 and N300 attached RLuc-HA expressed at 95.5% (±0.01, n=3) 
and 88.2% (±0.11, n=3) as compared to the control. Error bars, ±SEM. 










Brain-specific TPH2 was discovered more than a decade ago and has since 
been the subject of many research investigations targeting regulation of the 
central serotonin system. TPH2 regulation had been shown in many findings 
to play a role in the etiology of depressive disorders. The main focus of this 
study was to investigate the role of 5’UTR in TPH2 gene expression 
regulation. 
5’UTR, an important factor in the regulation of gene expression, was reported 
to affect the initiation, translation efficiency and mRNA stability in post-
transcriptional processes (Minet, Ernest et al. 1999, McCormick, Lyons et al. 
2000, Singh, He et al. 2002). As the basal transcription apparatus also 
contains partial sequence downstream of the transcription start site, it is 
suggested that 5’UTR might affect gene expression via a transcriptional 
mechanism. The role of the 5’UTR in the regulation of gene expression had 
been shown to be important in a number of genes such as Hypoxia-inducible 
factor 1-alpha (HIF1A) (Minet, Ernest et al. 1999), Murine Tumor Necrosis 
Factor-α (Singh, He et al. 2002), glucocorticoid receptor (McCormick, Lyons 
et al. 2000) and interleukin-5 receptor (Zhang, Cohn et al. 1997).  
In order to study the effect of 5’UTR on TPH2 gene expression regulation, the 
full length of 5’UTR (+1 to +141) was fused with the human TPH2 gene. In 
vitro expression study on HEK cells showed a significant decrease in protein 
levels and mRNA abundance which is consistent with similar reported studies 
performed on RN46A and HEK-293 cells, where a specific segment (+8 to 
+53) of the hTPH2 5’UTR was shown to cause a significant decrease in 
luciferase activity and mRNA abundance, albeit with a negligible effect on 
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mRNA stability. Such repression of gene expression could be due to 
transcriptional mechanisms within this segment and the possible existence of 
negative cis-element(s) within the segment (Chen, Vallender et al. 2008). 
Bipartite RE-1 silencer of transcription/ neuron restrictive silencing factor 
(REST/NRSF) in the +9 to +35 segment of the 5’UTR (Patel, Bochar et al. 
2007), and two other transcription factors (IA-1 and Myf-3) were found to lie 
within the +8 to +53 segment in another separate study. Both NRSF and IA-1 
were found to be capable of causing transcriptional repression of TPH2 gene 
(Breslin, Zhu et al. 2002, Chen and Miller 2009). These findings implied that 
5’UTR possesses an inhibitory effect on the post-transcriptional mRNA 
process of TPH2 gene. The 5’UTR of human TPH2 was also found to have a 
high GC content of around 60% with a predicted free energy of -36.12 
kcal/mol, which is likely to result in poorly translated mRNA transcript 
(Davuluri, Suzuki et al. 2000).  
Interestingly, an increase in protein level and upregulation of mRNA 
abundance were observed when PC12 cells were used to investigate the 
TPH2 gene expression. This is in contrast to reported findings that 5’UTR 
causes downregulation or repression of a gene during translation and in some 
cases transcription processes. To date, such observation on PC12 cells has 
not been reported. The closest reference was a report in 2002, prior to the 
identification of TPH2 where the isoforms of TPH were still referred to as 
TPHα and TPHβ. TPHβ, which is 51 nucleotides longer than the more 
abundant TPHα, shared many similarities to the current definition of TPH2. 
5’UTR of TPHα and TPHβ were each cloned upstream of a luciferase reporter 
gene. It was observed that TPHβ 5’UTR with a shorter half-life could increase 
the luciferase activity by two folds compared to TPHα 5’UTR in PC12 cells 
(Chamas and Sabban 2002).  
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Upon realizing the contrasting observation of the effect of 5’UTR in the 
regulation of TPH2 gene expression in HEK and PC12 cells, the specificity of 
the human TPH2 5’UTR was investigated by cloning the 5’UTR upstream and 
in-frame with the luciferase reporter gene (RLuc) and the enhanced green 
fluorescent protein gene (EGFP). In both cases, the reporter gene was 
directly attached to the regulatory elements, the 5’UTR, to create a fusion 
gene, where the 5’UTR and the reporter gene are transcribed into a single 
messenger RNA molecule. The mRNA was then translated into protein and 
the activity or expression levels could be measured.  5’UTR had an overall 
inhibitory effect on both the reporter genes and the same effect was also 
observed in PC12 cells.  
To clarify whether transcriptional or post-transcriptional mechanisms were 
involved in the regulation of luciferase expression, we also assessed RLuc 
mRNA levels by using qPCR. In the 5’UTR fused RLuc gene, a significant 
decrease in the reporter gene was observed in bioluminescence assay, semi-
qPCR and Western blot. In the 5’UTR fused EGFP, a decrease in protein 
level was observed in both cell lines while qPCR analysis showed a steep 
decrease in mRNA abundance in the HEK cells. These findings suggested 
that 5’UTR of hTPH2 could affect regulation of other heterologous gene via a 
transcriptional mechanism and/or post-transcriptionally. 
The repressive effect of 5’UTR during translation is well studied and it was 
verified in this report that protein expressions of the 5’UTR attached gene 
were fully inhibited in both cell lines except that of the homologous gene in 
PC12 cells. The hypothesis that this inhibition might have occurred at an early 
stage of gene expression, thus investigated the transcription stages of gene 
expression using an inducible gene expression system. For this study, the 
Tet-On, a tetracycline-controlled transcriptional activation system where 
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transcription could be turned on in the presence of the doxycycline was used 
in our experimental approaches (Clontech Laboratories 2014). The reversible 
Tet system is preferred to other irreversible conditional gene expression 
systems such as Cre recombinase and estrogen receptor (ER) as it provides 
tighter control. The Tet system reduces basal expression and promotes tight 
binding to the trans-activator protein during induction, permitting specific and 
high-level transcription of the downstream gene (Gossen and Bujard 1992, 
Urlinger, Baron et al. 2000). It is however not as fast-acting as the ER system, 
where upon hormone administration, stabilizes the already-expressed target 
protein. . The Tet system, on the other hand, requires more time before a 
change in the levels of protein product can be observed, due to the need for 
transcription and translation of the target gene (Sohal, Nghiem et al. 2001).  
The function of 5’UTR was further examined by substituting the homologous 
TPH2 gene with the heterologous EGFP gene. The same experiment as 
described above was conducted using the same Tet inducible system and it 
was found that similar downregulation of the mRNA abundance was observed 
for pT-5U-EGFP. In order to eliminate any 5’UTR effect that might occur 
during translation, the start codon (AUG, Methionine) was removed in a 
separate experiment and tested in HEK cells where again, a downregulation 
of mRNA abundance was observed, consistent with earlier studies. This 
observation suggests that 5’UTR indeed represses gene expression at the 
early transcriptional stage independent of post-transcriptional stages as 
widely reported.  
The observed upregulation of TPH2 by 5’UTR in PC12 cells remained to be 
investigated. The investigation started by first focusing on the identification of 
potential transcriptional mechanisms which might be responsible for the 
upregulation. Since it is known that REST/NRSF in the +9 to +35 segment 
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and the +8 to +53 segment cause a significant decrease in luciferase activity 
and mRNA level (Patel, Bochar et al. 2007, Chen, Vallender et al. 2008) were 
referred. Two truncated 5’UTRs were generated consisting of +36 to +141 
subtype and +86 to +141 subtype in an attempt to remove these elements. 
When both truncated 5’UTRs were fused with the heterologous gene, RLuc, 
there were no significant changes observed in the luciferase activity observed 
for both the truncated 5’UTR compared with full length 5’UTRs. The 
expression profiles were consistently similar for both HEK and PC12 cells. 
We then fused the truncated 5’UTRs with the homologous gene, TPH2, and 
investigated their respective expression profiles in PC12 cells. The full length 
5’UTR resulted in a marked increase in protein level, while truncated 5’UTR 
resulted in an increase of smaller amplitude. This observation supports our 
above mentioned findings that in PC12 cells, the 5’UTR affects TPH2 
expression in opposing manner compared with HEK cells. It also shows that 
the full length 5’UTR is necessary to elicit a maximal upregulation of TPH2 
expression. 
Determine the essential domains of the TPH2 gene that is required to achieve 
maximal upregulation in PC12 cells was sought after.  Several truncated 
TPH2 constructs were made and attached upstream of the luciferase gene. It 
was observed that in HEK cells that the full length 5’UTR has a uniform 
repressive effect on the TPH2 gene regardless of length. However, in PC12 
cells, no upregulation of luciferase activity was observed for truncated TPH2 
constructs. Therefore, it seems that the entire TPH2 gene is essential for 
interaction with 5’UTR, in order to elicit a maximal upregulation of protein 
expression.  
From the results shown in this study, the hypothesis that a neuronal specific 
factor(s) that is present only in PC12 might be responsible for the 5’UTR 
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upregulatory effect on the THP2 expression was suggested. We speculate 
that the neuronal specific factor(s) might be an interacting protein that binds 
to regions within the 5’UTR sequence. These regions could possibly be the 
binding sites of transcription factors that are known to cause transcriptional 
repression, and thus such interactions might have abolished the repression 
effect of 5’UTR in PC12 cells and upregulates TPH2 gene expression. The 
upregulatory effect of 5’UTR that was absent in HEK cells could probably be 
due to the absence of these neuronal specific factor(s) in epithelial cells.  
It was shown that transfection with the 5’UTR has a general effect of 
decreasing gene exporession, except where full length TPH2, and 
presumably serotonin, is produced. The presence of tyrosine hydroxylase (TH) 
might be one of the many undiscovered reasons as to why the upregulation of 
gene expression was observed only in PC12 cells.  PC12 cells contain TH 
and thus contain all the cellular machinary necessary to support amino acid 
hydroxylase function, whereas HEK cells do not. A more in-depth studies that 
explore the interactions of TH, serotonin and 5’UTR of TPH2 could be the 
next focus of this project.   
In conclusion, results of our study suggests that the role that 5’UTR plays in 
regulating protein expression, which may be up or downregulation, is 
dependent an optimal set of conditions. This is likely to be determined by both 
the cellular and gene environment, and their interactions. Since current anti-
depressant treatments centred around the regulation of the serotonergic 
system, we showed that the 5’UTR can regulate serotonin production and 
therefore may serve as a novel target for therapeutic interventions. In order to 
be able to manipulate 5’UTR into upregulating TPH2 expression, further 
studies are needed to better understand what aspects of the cell environment 
causes the switch in regulatory roles of the 5’UTR. 
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5. Future Work 
The next action for this study would be to identify the neuronal specific factors 
of PC12 cells that are responsible for causing this cell type specific 
enhancement of TPH2 expression mediated by the 5’UTR. This can be done 
by expanding the repertoire; screening more neuronal related cell lines and 
finding another cell line that can recapitulate the effect seen in PC12 cells. 
This other cell line can then be compared with PC12 cells to identify common 
factors that can allow for a 5’UTR mediated increase of TPH2 expression. 
Several cell lines have since been screened, including the human brain 
neuroblastoma (SH-SY5Y), mouse brain neuroblastoma (Neuro-2a), mouse 
embryo fibroblast (NIH-3T3). However, none have shown this enhancing 
effect. As such, more cell lines will have to be acquired and tested. 
With regards to the hypothesis that the neuronal specific factor might be an 
interacting protein, proving the presence of a protein-RNA complex would be 
of foremost interest. RNA-Electrophoretic Mobility Shift Assay (RNA-EMSA) is 
an in vitro technique that is commonly used to detect such complexes through 
the changes in gel electrophoresis migration patterns. A biotinylated RNA 
probes that mimics the 5’UTR can be commercially purchased and incubate 
with cell lysates of either the HEK or PC12 cells; and comparing the migration 
patterns would allow us to know if there is an interacting protein. If a protein-
RNA complex is identified, more in-depth studies can then be carried to 
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